Great Achievements Have Been Made in the Field of Single Domain Antibody
Antibody can be regarded as a specific protein produced in response to counteract a unique
antigen that is usually used to recognize and resist the invaders. It can combine chemically with
the substances that the body recognizes as outsiders such as bacteria and viruses. Thus, people can
reduce the levels of that special substance through introducing it into antibody. With the immune
system, antibody can release a defensive protein, including molecular markers, for research of
those destroyed diseased cells.
With the rapid development of antibody technology, single domain antibodies, also known as
camelid antibodies, can also accomplish the same task. Because its small body is accessible to the
restricted area of macromolecules much easier, single domain antibody shows a more attractive
prospect. However, there are still some difficulties remained to achieve the goal, since scientists
haven’t found yet an effective method to identify this kind of antibody. Fortunately, this problem
has been solved by researchers from Rockefeller University. They have developed a new
successful technology which can ensure that single domain antibody will significantly meet the
needs of massive researching fields. The key is to find a relatively quick way to determine the
gene sequence of high-affinity single domain antibody, because once those sequences are obtained,
it’s easy to conduct massive production of such antibodies utilizing bacteria.
Researchers first inoculate GFP and mCherry for the llamas, helping their immune system to fight
against antibody of the two foreign proteins and then extracting RNA from llamas’
antibody-producing cells for the purpose of establishing an antibody sequence database. After
follow-up several procedures, the most high affinity antibody can be paired with those original
RNA sequences with the help of computer program named “llama magic”. Based on this new
sequence, researchers have produced 25 kinds of single domain antibody that can precisely target
GFP and six kinds at mCherry with a higher efficiency.
This new sequence has aroused a new inspiration. Scientists can choose the most high-affinity
single domain antibody and occasionally abandon those ungraded products, declining the required
amount and reducing the side effects to a better degree. In short, modern single domain antibody
technology is able to identify high-affinity single domain antibody.
About Author
Creative Biolabs is a professional biotech service provide specialized in the antibody development
and research. As a trusted provider of the most cost-effective outsourcing solutions, Creative
Biolabs has been working for a large number of satisfied clients from biotechnology and
pharmaceutical companies as well as government and academic research laboratories all over the
world.
http://www.wikigenes.org/e/pub/e/59079.html
https://articles.abilogic.com/submission-completed/0/ pending
https://medium.com/@tangyuanyuan181/great-achievements-have-been-made-in-the-field-of-si
